Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait
Affiliations
Affiliations
- Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait; Neurology Clinic, Department of Medicine, Dasman Diabetes Institute, Dasman, Kuwait. Electronic address: alroughani@gmail.com.
- Department of Neurology, Ibn Sina Hospital, Kuwait City, Kuwait; Department of Neurology & Psychiatry, Al-Minia University Hospital, Minia, Egypt.
- Neurology Clinic, Department of Medicine, Dasman Diabetes Institute, Dasman, Kuwait.
- Department of Neurology, Ibn Sina Hospital, Kuwait City, Kuwait; Department of Medicine, Kuwait University, Jabriya, Kuwait.
Abstract
Background: Post-marketing studies are important to confirm what was established in clinical trials, and to assess the intermediate and long-term efficacy and safety.
Objective: To assess efficacy and safety of fingolimod in multiple sclerosis (MS) in Kuwait.
Methods: We retrospectively evaluated MS patients using the MS registries in 3 MS clinics. Relapsing remitting MS patients according to revised 2010 McDonald criteria who had been treated with fingolimod for at least 12 months were included. Primary endpoint was proportion of relapse-free patients at last follow-up. Secondary endpoints were mean change in EDSS and proportion of patients with MRI activity (gadolinium-enhancing or new/enlarging T2 lesions).
Results: 76 patients met the inclusion criteria. Mean age and mean disease duration were 34.43 and 7.82 years respectively. Mean duration of exposure to fingolimod was 18.50 months. Proportion of relapse-free patients was 77.6% at last follow-up. Mean EDSS score significantly improved (2.93 versus 1.95; p<0.0001) while 17.1% of patients continued to have MRI activity versus 77.6% at baseline (p<0.0001). Four patients stopped fingolimod due to disease breakthrough (n=3) and lymphadenitis (n=1).
Conclusion: Fingolimod is safe and effective in reducing clinical and radiological disease activity in relapsing remitting MS patients. Our results are comparable to reported results of phase III studies.
Keywords: Fingolimod; Multiple sclerosis; Outcome measures; Treatment.
Similar articles
Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R.CNS Drugs. 2014 Sep;28(9):817-24. doi: 10.1007/s40263-014-0185-z.PMID: 25011422
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.PMID: 20089952 Clinical Trial.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.PMID: 20089954 Clinical Trial.
Management of fingolimod in clinical practice.
Thomas K, Ziemssen T.Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S60-4. doi: 10.1016/j.clineuro.2013.09.023.PMID: 24321158 Review.
Fingolimod for relapsing multiple sclerosis: an update.
Horga A, Castilló J, Montalban X.Expert Opin Pharmacother. 2010 May;11(7):1183-96. doi: 10.1517/14656561003769866.PMID: 20367536 Review.
Cited by
Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis.
Yavari F, Oliazadeh P, Radfar M, Foroughipour M, Nikkhah K, Heidari Bakavoli A, Saeidi M.Basic Clin Neurosci. 2021 Mar-Apr;12(2):233-242. doi: 10.32598/bcn.12.2.1681.1. Epub 2021 Mar 1.PMID: 34925720 Free PMC article.
Zecca C, Roth S, Findling O, Perriard G, Bachmann V, Pless ML, Baumann A, Kamm CP, Lalive PH, Czaplinski A.Eur J Neurol. 2018 May;25(5):762-767. doi: 10.1111/ene.13594. Epub 2018 Mar 6.PMID: 29431876 Free PMC article.
Achiron A, Aref H, Inshasi J, Harb M, Alroughani R, Bijarnia M, Cooke K, Yuksel O.BMC Neurol. 2017 Aug 7;17(1):150. doi: 10.1186/s12883-017-0913-3.PMID: 28784108 Free PMC article.
Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G.PLoS One. 2017 Apr 28;12(4):e0176174. doi: 10.1371/journal.pone.0176174. eCollection 2017.PMID: 28453541 Free PMC article.